Detalhe da pesquisa
1.
Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials.
Br J Dermatol
; 190(5): 668-679, 2024 Apr 17.
Artigo
Inglês
| MEDLINE | ID: mdl-38226713
2.
Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b study.
J Am Acad Dermatol
; 2024 Mar 28.
Artigo
Inglês
| MEDLINE | ID: mdl-38554938
3.
Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis.
J Am Acad Dermatol
; 90(4): 775-782, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38122848
4.
Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials.
Br J Dermatol
; 188(2): 198-207, 2023 02 10.
Artigo
Inglês
| MEDLINE | ID: mdl-36763857
5.
Oral spleen tyrosine kinase/Janus Kinase inhibitor gusacitinib for the treatment of chronic hand eczema: Results of a randomized phase 2 study.
J Am Acad Dermatol
; 89(2): 235-242, 2023 08.
Artigo
Inglês
| MEDLINE | ID: mdl-37094653
6.
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.
J Am Acad Dermatol
; 88(1): 40-51, 2023 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36115523
7.
Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial.
J Am Acad Dermatol
; 86(1): 77-85, 2022 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34343599
8.
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
N Engl J Med
; 376(16): 1551-1560, 2017 04 20.
Artigo
Inglês
| MEDLINE | ID: mdl-28423301
9.
Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study.
J Am Acad Dermatol
; 83(1): 96-103, 2020 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-32032692
10.
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Lancet
; 392(10148): 650-661, 2018 08 25.
Artigo
Inglês
| MEDLINE | ID: mdl-30097359
11.
Perspectives on Living with Chronic Spontaneous Urticaria: From Onset through Diagnosis and Disease Management in the US.
Acta Derm Venereol
; 99(12): 1091-1098, 2019 Nov 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31396637
12.
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT).
J Am Acad Dermatol
; 79(2): 266-276.e5, 2018 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-29660425
13.
Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE).
J Am Acad Dermatol
; 78(5): 863-871.e11, 2018 05.
Artigo
Inglês
| MEDLINE | ID: mdl-29353026
14.
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.
Lancet
; 387(10013): 40-52, 2016 Jan 02.
Artigo
Inglês
| MEDLINE | ID: mdl-26454361
15.
A reliability study using Network-Oriented Research Assistant to evaluate the use of digital photographs in the assessment of atopic dermatitis.
J Am Acad Dermatol
; 85(3): 725-726, 2021 09.
Artigo
Inglês
| MEDLINE | ID: mdl-30703454
16.
A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma.
J Am Acad Dermatol
; 73(1): 99-105.e1, 2015 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-25913533
17.
Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.
J Allergy Clin Immunol
; 133(4): 1032-40, 2014 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-24679469
18.
Pharmacokinetics, safety, and efficacy of cedirogant from phase I studies in healthy participants and patients with chronic plaque psoriasis.
Clin Transl Sci
; 17(1): e13682, 2024 01.
Artigo
Inglês
| MEDLINE | ID: mdl-38112262
19.
Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.
Lancet
; 380(9843): 738-46, 2012 Aug 25.
Artigo
Inglês
| MEDLINE | ID: mdl-22748702
20.
Omalizumab response in patients with chronic idiopathic urticaria: Insights from the XTEND-CIU study.
J Am Acad Dermatol
; 78(4): 793-795, 2018 04.
Artigo
Inglês
| MEDLINE | ID: mdl-29037993